Artal Group’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,304,127
| Closed | -$14.8M | – | 131 |
|
|
2023
Q4 | $14.8M | Buy |
1,304,127
+1,204,127
| +1,204% | +$9.46M | 0.49% | 29 |
|
|
2023
Q3 | $403K | Hold |
100,000
| – | – | 0.02% | 88 |
|
|
2023
Q2 | $710K | Hold |
100,000
| – | – | 0.02% | 95 |
|
|
2023
Q1 | $744K | Hold |
100,000
| – | – | 0.04% | 97 |
|
|
2022
Q4 | $726K | Hold |
100,000
| – | – | 0.04% | 110 |
|
|
2022
Q3 | $970K | Hold |
100,000
| – | – | 0.04% | 115 |
|
|
2022
Q2 | $1.91M | Hold |
100,000
| – | – | 0.1% | 99 |
|
|
2022
Q1 | $4.97M | Hold |
100,000
| – | – | 0.21% | 78 |
|
|
2021
Q4 | $7.55M | Hold |
100,000
| – | – | 0.2% | 81 |
|
|
2021
Q3 | $7.9M | Hold |
100,000
| – | – | 0.18% | 94 |
|
|
2021
Q2 | $13.9M | Hold |
100,000
| – | – | 0.28% | 72 |
|
|
2021
Q1 | $20.9M | Buy |
100,000
+20,000
| +25% | +$4.01M | 0.37% | 62 |
|
|
2020
Q4 | $13.3M | Hold |
80,000
| – | – | 0.29% | 80 |
|
|
2020
Q3 | $13.6M | Sell |
80,000
-10,000
| -11% | -$1.44M | 0.33% | 65 |
|
|
2020
Q2 | $14.9M | Sell |
90,000
-30,000
| -25% | -$4.68M | 0.42% | 54 |
|
|
2020
Q1 | $13.9M | Buy |
120,000
+35,000
| +41% | +$4.92M | 0.59% | 38 |
|
|
2019
Q4 | $12.6M | Buy |
+85,000
| New | +$12.9M | 0.49% | 37 |
|
Artal Group's HARP Position: Q1 2024 in Review
Artal Group sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 1,304,127 shares — an estimated $14.8M sold.
Artal Group first reported a position in HARP in Q4 2019 and held it in 17 quarters. The position peaked at $20.9M in Q1 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Artal Group reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Artal Group sold 1,304,127 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $14.8M.
- Artal Group first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
- Artal Group's Harpoon Therapeutics, Inc. Common Stock position peaked at $20.9M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.